Han-Joo Kim

Company: IMNEWRUN

Job title: Chief Executive Officer

Seminars:

Workshop A: Next-Generation Blood-Brain Barrier Penetrant Therapeutic Antibodies 8:00 am

The recent approval of anti-Aβ antibodies has ushered in new possibilities and challenges in the realm of neurodegenerative diseases. A significant hurdle lies in the blood-brain barrier, permitting only 0.01-0.1% of antibodies to traverse into the brain, primarily through cerebrospinal fluid. The pivotal and complex challenge of achieving selective delivery of therapeutic antibodies with high…Read more

day: Pre-Conference Workshop Day